1. Home
  2. ERC vs ZNTL Comparison

ERC vs ZNTL Comparison

Compare ERC & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Allspring Multi-Sector Income Fund

ERC

Allspring Multi-Sector Income Fund

HOLD

Current Price

$8.98

Market Cap

260.9M

Sector

Finance

ML Signal

HOLD

Logo Zentalis Pharmaceuticals Inc.

ZNTL

Zentalis Pharmaceuticals Inc.

HOLD

Current Price

$3.73

Market Cap

289.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ERC
ZNTL
Founded
2003
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
260.9M
289.0M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
ERC
ZNTL
Price
$8.98
$3.73
Analyst Decision
Buy
Analyst Count
0
5
Target Price
N/A
$6.60
AVG Volume (30 Days)
93.9K
975.7K
Earning Date
01-01-0001
05-07-2026
Dividend Yield
8.37%
N/A
EPS Growth
N/A
18.03
EPS
0.72
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$12.40
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.72
$1.13
52 Week High
$9.78
$6.95

Technical Indicators

Market Signals
Indicator
ERC
ZNTL
Relative Strength Index (RSI) 44.30 45.43
Support Level $8.90 $3.44
Resistance Level $9.23 $4.38
Average True Range (ATR) 0.10 0.25
MACD -0.01 -0.04
Stochastic Oscillator 30.94 35.46

Price Performance

Historical Comparison
ERC
ZNTL

About ERC Allspring Multi-Sector Income Fund

Allspring Multi-Sector Income Fund is a closed-end investment management company. The company's core business is to secure a high level of income for its investors consistent with limiting its overall exposure to domestic interest rate risk. It invests in U.S. dollar-denominated below investment-grade bonds, debentures, and other income obligations, including loans and preferred stocks, developed and emerging market debt securities, including obligations of foreign governments or governmental entities, foreign corporations, or supranational agencies denominated in various currencies, asset backed securities and investment grade corporate bonds.

About ZNTL Zentalis Pharmaceuticals Inc.

Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.

Share on Social Networks: